153 related articles for article (PubMed ID: 23742289)
1. proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke.
Rodríguez JA; Sobrino T; Orbe J; Purroy A; Martínez-Vila E; Castillo J; Páramo JA
J Thromb Haemost; 2013 Aug; 11(8):1464-73. PubMed ID: 23742289
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA.
Moldes O; Sobrino T; Millán M; Castellanos M; Pérez de la Ossa N; Leira R; Serena J; Vivancos J; Dávalos A; Castillo J
Stroke; 2008 Jul; 39(7):2006-10. PubMed ID: 18436890
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
Kelly PJ; Morrow JD; Ning M; Koroshetz W; Lo EH; Terry E; Milne GL; Hubbard J; Lee H; Stevenson E; Lederer M; Furie KL
Stroke; 2008 Jan; 39(1):100-4. PubMed ID: 18063832
[TBL] [Abstract][Full Text] [Related]
4. Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
Lin J; Han Z; Yi X; Luo H; Zhou Q; Zhou J
J Atheroscler Thromb; 2019 Jun; 26(6):528-537. PubMed ID: 30429408
[TBL] [Abstract][Full Text] [Related]
5. The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
Lasek-Bal A; Jedrzejowska-Szypulka H; Student S; Warsz-Wianecka A; Zareba K; Puz P; Bal W; Pawletko K; Lewin-Kowalik J
J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31356182
[TBL] [Abstract][Full Text] [Related]
6. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
[TBL] [Abstract][Full Text] [Related]
7. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
Millan M; Sobrino T; Castellanos M; Nombela F; Arenillas JF; Riva E; Cristobo I; García MM; Vivancos J; Serena J; Moro MA; Castillo J; Dávalos A
Stroke; 2007 Jan; 38(1):90-5. PubMed ID: 17138950
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
[TBL] [Abstract][Full Text] [Related]
9. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
[TBL] [Abstract][Full Text] [Related]
10. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation.
Tu HT; Campbell BC; Christensen S; Desmond PM; De Silva DA; Parsons MW; Churilov L; Lansberg MG; Mlynash M; Olivot JM; Straka M; Bammer R; Albers GW; Donnan GA; Davis SM;
Int J Stroke; 2015 Jun; 10(4):534-40. PubMed ID: 23489996
[TBL] [Abstract][Full Text] [Related]
11. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
Castellanos M; Leira R; Serena J; Blanco M; Pedraza S; Castillo J; Dávalos A
Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391
[TBL] [Abstract][Full Text] [Related]
12. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
Castellanos M; Sobrino T; Millán M; García M; Arenillas J; Nombela F; Brea D; Perez de la Ossa N; Serena J; Vivancos J; Castillo J; Dávalos A
Stroke; 2007 Jun; 38(6):1855-9. PubMed ID: 17478737
[TBL] [Abstract][Full Text] [Related]
13. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
14. Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients.
Bogoslovsky T; Spatz M; Chaudhry A; Maric D; Luby M; Frank J; Warach S
J Transl Med; 2011 Aug; 9():145. PubMed ID: 21871109
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and inflammatory biomarkers in ischemic stroke: translational study between humans and two experimental rat models.
Martínez-Sánchez P; Gutiérrez-Fernández M; Fuentes B; Masjuán J; Cases MA; Novillo-López ME; Díez-Tejedor E;
J Transl Med; 2014 Aug; 12():220. PubMed ID: 25086655
[TBL] [Abstract][Full Text] [Related]
16. A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA).
Leira R; Sobrino T; Blanco M; Campos F; Rodríguez-Yáñez M; Castellanos M; Moldes O; Millán M; Dávalos A; Castillo J
Clin Sci (Lond); 2012 Feb; 122(3):113-9. PubMed ID: 21861843
[TBL] [Abstract][Full Text] [Related]
17. Racial and gender differences in stroke severity, outcomes, and treatment in patients with acute ischemic stroke.
Boehme AK; Siegler JE; Mullen MT; Albright KC; Lyerly MJ; Monlezun DJ; Jones EM; Tanner R; Gonzales NR; Beasley TM; Grotta JC; Savitz SI; Martin-Schild S
J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):e255-61. PubMed ID: 24468069
[TBL] [Abstract][Full Text] [Related]
18. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
[TBL] [Abstract][Full Text] [Related]
19. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tsuji K; Aoki T; Tejima E; Arai K; Lee SR; Atochin DN; Huang PL; Wang X; Montaner J; Lo EH
Stroke; 2005 Sep; 36(9):1954-9. PubMed ID: 16051896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
